Lundbeck Launches Rexulti In Europe, Phase II LU AF11167 Trial In Schizophrenia
Danish CNS specialist begins Rexulti roll-out in Europe and proof-of-concept study of its early pipeline candidate Lu AF11167.
You may also be interested in...
The first Phase III study for Lundbeck’s novel antipsychotic flops leaving the Danish company shares down by 25% as investors wonder what’s left in the pipeline.
With a new CEO taking the reins in September and a candidate entering the clinic for Parkinson’s disease, Lundbeck has opportunities for refreshment, both in the pipeline and the boardroom. But with generic competition battering down the company’s financial outlook, it may not be enough to bring the market along for the ride.
Denmark's mid-sized biopharma, Lundbeck, has taken another potential Parkinson's disease therapeutic into early clinical studies, the third this year, and this time it's a monoclonal antibody, not a small molecule.